KR101825603B1 - Composition of skin external application for improving alopecia containing Oldenlandia Diffusa Willd extracts - Google Patents
Composition of skin external application for improving alopecia containing Oldenlandia Diffusa Willd extracts Download PDFInfo
- Publication number
- KR101825603B1 KR101825603B1 KR1020170062536A KR20170062536A KR101825603B1 KR 101825603 B1 KR101825603 B1 KR 101825603B1 KR 1020170062536 A KR1020170062536 A KR 1020170062536A KR 20170062536 A KR20170062536 A KR 20170062536A KR 101825603 B1 KR101825603 B1 KR 101825603B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- hair
- agents
- cosmetic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000000284 extract Substances 0.000 title claims abstract description 37
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 21
- 240000001659 Oldenlandia diffusa Species 0.000 title description 2
- 231100000360 alopecia Toxicity 0.000 title 1
- 208000024963 hair loss Diseases 0.000 claims abstract description 19
- 230000003676 hair loss Effects 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 230000003752 improving hair Effects 0.000 claims abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 210000004209 hair Anatomy 0.000 claims description 18
- 235000014676 Phragmites communis Nutrition 0.000 claims description 12
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 11
- 239000000049 pigment Substances 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 8
- 239000003205 fragrance Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 208000003351 Melanosis Diseases 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- -1 softeners Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000004088 foaming agent Substances 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000003352 sequestering agent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims 1
- 239000004503 fine granule Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000002087 whitening effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 15
- 206010000496 acne Diseases 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- 230000002421 anti-septic effect Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 229920002498 Beta-glucan Polymers 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229930182478 glucoside Natural products 0.000 description 5
- 150000008131 glucosides Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 4
- 229960003473 androstanolone Drugs 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000002985 plastic film Substances 0.000 description 4
- 229910052573 porcelain Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229950011392 sorbitan stearate Drugs 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000220259 Raphanus Species 0.000 description 3
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- MUMGGOZAMZWBJJ-JQSYSRDDSA-N (8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13-dimethyl-1,2,6,7-tetratritio-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2C([3H])C([3H])C3=CC(=O)C([3H])C([3H])[C@]3(C)[C@H]21 MUMGGOZAMZWBJJ-JQSYSRDDSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241000530454 Litopenaeus schmitti Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- LPGFSDGXTDNTCB-UHFFFAOYSA-N [3-(16-methylheptadecanoyloxy)-2,2-bis(16-methylheptadecanoyloxymethyl)propyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC(C)C)(COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C LPGFSDGXTDNTCB-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012754 barrier agent Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- LVQSCKUKDKAQGO-UHFFFAOYSA-L disodium;diiodide Chemical compound [Na+].[Na+].[I-].[I-] LVQSCKUKDKAQGO-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002910 effect on acne Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000010487 meadowfoam seed oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 탈모를 개선시킬 수 있는 피부 외용제 조성물에 관한 것으로, 보다 상세하게는 백화사설초 추출물을 유효성분으로 함유하여 우수한 5-알파 리덕타아제 저해 효과를 통해 탈모를 개선시키는 피부 외용제 조성물에 관한 것이다.The present invention relates to a composition for external application for skin which can improve hair loss, and more particularly, to a composition for external application for skin which contains white blood powdery extract as an active ingredient and improves hair loss through excellent 5-alpha-lyudactase inhibitory effect .
Description
본 발명은 탈모를 개선시킬 수 있는 피부 외용제 조성물에 관한 것으로, 보다 상세하게는 백화사설초 추출물을 유효성분으로 함유하여 우수한 5-알파 리덕타아제 저해 효과를 통해 탈모를 개선시키는 피부 외용제 조성물에 관한 것이다.The present invention relates to a composition for external application for skin which can improve hair loss, and more particularly, to a composition for external application for skin which contains white blood powdery extract as an active ingredient and improves hair loss through excellent 5-alpha-lyudactase inhibitory effect .
5-알파 리덕타아제는 피지선, 모낭, 전립선, 부고환 등의 남성 호르몬 반응성 조직에서 존재하며 남성 호르몬들 중 하나인 테스토스테론(Testosterone)을 디히드로테스토스테론(Dihydrotestosterone)으로 대사시키는 데에 관여하는 효소로서 그 전환에는 NADPH를 필요로 한다. 남성 성충동, 골격근 증가, 남성 외부 생식기, 음낭성장, 정자형성 등은 테스토스테론이 관여하고 여드름, 피지증가, 탈모 및 전립선비대증 등은 디히드로테스토스테론이 해당 조직에서 관여한다(Diane et al.J.I.D. 1995). 따라서, 이 효소를 억제할 수 있는 약제를 찾아내어 여드름 치료제, 피지분비 억제제 및 탈모 방지제로 개발하려는 연구들이 활발히 진행되고 있다. 사춘기 이후에 남성 호르몬의 과량 분비는 여드름과 탈모를 유발하는데, 모낭의 모유두 세포에서의 디히드로테스토스테론 과량 생성을 막기 위해 5-알파 리덕타아제 억제 활성을 갖는 육모제나 탈모 방지제를 개발하려는 연구들이 활발히 진행되고 있다.5-alpha reductase is an enzyme involved in the metabolism of testosterone, one of the male hormones, testosterone, into dihydrotestosterone, which exists in the male hormone-responsive tissues of sebaceous gland, hair follicle, prostate and epididymis. Conversion requires NADPH. (Diane et al., J.I.D. 1995). The testosterone is involved in male sexual dysfunction, skeletal muscle increase, male genitalia, scrotum growth, and spermatogenesis, and acne, sebum increase, hair loss and enlargement of the prostate are involved in the tissues of dihydrotestosterone. Therefore, researches are being actively carried out to develop a drug capable of inhibiting the enzyme and to develop it as an acne treatment agent, an sebaceous gland inhibitor, and an anti-hair loss agent. After puberty, excessive secretion of male hormone causes acne and hair loss. Studies to develop hair restorer or anti-hair restorer with 5-alpha-reductase inhibitory activity to prevent the production of dihydrotestosterone excess in follicular dermal papilla cells are actively conducted It is progressing.
여드름 치료나 남성형 탈모의 치료를 위해 종래에는 에스트로겐(estrogen) 등의 여성 호르몬을 사용하거나 5-알파 리덕타아제 억제제를 이용해왔다. 그러나 여성 호르몬제는 피부 염증 발생, 호르몬 투여에 의한 부작용 발생 등의 보고가 있어 현재는 사용을 중단하거나 아주 극미량을 사용하고 있는 실정이다. 최근에는 머크사에서 5-알파 리덕타아제 억제제인 피나스테라이드(finasteride)를 합성하여 먹는 육모제로 시판되고 있는 실정이나 고가라는 측면과 합성품에 기인한 부작용 등의 문제로 인해 사용에 제한을 받고 있는 실정이다.Traditionally, female hormones such as estrogen have been used for the treatment of acne and for the treatment of male pattern baldness or have used 5-alpha reductase inhibitors. However, female hormones have been reported to cause skin irritation and side effects due to hormone administration, and they are currently being discontinued or using extremely low doses. In recent years, Merck has limited the use of finasteride, a synthetic 5-alpha reductase inhibitor, due to the fact that it is commercially available as a hair restorer, and the side effects caused by synthetic products .
이에, 본 발명자들은 5-알파 리덕타아제의 저해 효과가 우수한 천연물을 찾고자 연구한 결과, 백화사설초가 5-알파 리덕타아제를 저해함으로써 탈모 개선 효과가 뛰어남을 발견하고 본 발명을 완성하였다.Accordingly, the inventors of the present invention have searched for natural products superior in the inhibitory effect of 5-alpha reductase, and found that white freunds were inhibited 5-alpha reductase and thus had excellent hair loss improving effect.
따라서, 본 발명의 목적은 5-알파 리덕타아제를 저해함으로써 탈모 개선 효과가 우수한 피부 외용제 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a composition for external application for skin which is superior in improving hair loss by inhibiting 5-alpha reductase.
상기 목적을 달성하기 위하여, 본 발명은 백화사설초 추출물을 유효성분으로 함유하는 탈모 개선용 피부 외용제 조성물을 제공한다.In order to accomplish the above object, the present invention provides a composition for external application for skin for improving hair loss, which comprises an extract of Bacillus subtilis as an active ingredient.
본 발명에 의해 제공되는 피부 외용제 조성물은 백화사설초 추출물을 유효성분으로 함유하여 5-알파 리덕타아제의 작용을 효과적으로 저해함으로써 탈모 개선 효과가 매우 우수하고 천연물을 사용하여 인체에 매우 안전하다. 그러므로 본 발명을 통해 탈모 개선에 효과적인 피부 외용제 조성물을 제공할 수 있다.The composition for external application for skin provided by the present invention contains an extract of Bacillus subtilis as an effective ingredient to effectively inhibit the action of 5-alpha reductase and thus is very safe for the human body by using natural products. Therefore, the present invention can provide a skin external composition for hair loss improvement.
본 발명은 백화사설초(Oldenlandia Diffusa Willd) 추출물을 유효성분으로 함유하는 탈모 개선용 피부 외용제 조성물을 제공한다.The present invention provides a composition for external application for skin for improving hair loss comprising an extract of Bacillus subtilis (Oldenlandia Diffusa Willd) as an active ingredient.
이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에서 유효성분으로 사용하는 백화사설초는 한의학뿐만 아니라, 민간요법으로도 널리 알려지고 사용되어온 한방약제의 하나이다. 백화사설초는 중국의 남부, 동남아시아, 제주도의 울창하고 그늘진 숲속에서 자생하는 꼭두서니과(Rubiaceae) 식물로 중국 전통의학에서 간암, 폐암, 직장암의 치료, 해열, 해독에 사용되어 왔다. 백화사설초에 함유된 성분으로는 베툴린(Betulin), 베툴릭산(Betulinic acid), 우루솔릭산(Ursolic acid), 올레아놀릭산(Oleanolic acid), 스티그마스테롤(Stigmasterol), 베타-시토스테롤(β-Sitosterol), 베타-글리시레티닉산(β-Glycyrretinic acid), 펜타-쿠마릭산(ρ-Coumaric acid), 글루코사이드(Glucoside), 헨트리아콘테인(Hentriacontane) 등이 있으며 항암활성, 항염증효과 및 항바이러스효과를 나타낸다고 알려져 있다.In the present invention, Bacillus specialis used as an active ingredient is one of herbal medicine widely known and used not only in Oriental medicine but also in folk medicine. Baekhwa is a Rubiaceae plant that grows in the lush and shady forests of southern China, Southeast Asia, and Jeju Island. It has been used in traditional Chinese medicine for the treatment of liver cancer, lung cancer, rectal cancer, Betulin, Betulinic acid, Ursolic acid, Oleanolic acid, Stigmasterol, Beta-sitosterol, etc. are contained in the Baekhwa exclusive use. , Β-Glycyrrhetinic acid, p-Coumaric acid, Glucoside, Hentriacontane, etc., and have anticancer activity, anti-inflammatory effect and antiviral effect Lt; / RTI >
본 발명의 백화사설초 추출물은 당업계에 공지된 방법에 따라 제조될 수 있으며, 그 방법은 특별히 한정되지 않는다. 구체적인 예를 들면, 백화사설초를 자연건조하여 잘게 분쇄한 분쇄물에 대해 추출 용매로서 물, 저급 알코올(메탄올, 에탄올), 물과 저급 알코올의 혼합물, 아세톤, 1,3-부틸렌글리콜, 노말프로판올, 이소프로판올, 노말부탄올 등의 극성용매와 이것들의 혼합용매를 5~20배 부피량으로 가하여 침적 추출하여 여과한 후 여액을 감압농축한다. 농축액에 물을 가하여 분산시킨 후 분산액에 동량의 에틸아세테이트, 클로로포름, 디에틸에테르 등의 저극성 유기 용매를 가하고 진탕한다. 유기층을 분리한 후 감압농축하여 활성이 우수한 추출물을 얻는다. 추출 방법으로는 냉침과 페르콜레이션의 경우는 12~96시간, 또는 탄소수 1~4개의 무수 또는 함수 저급 알코올, 에틸아세테이트 또는 디에틸에테르를 용매로 하여 4~25℃ 상온에서 3~20일 방치 숙성시켜서 유효성분을 추출할 수도 있다. 온침의 경우는 사용하는 용매 등의 종류와 온도에 따라서 상이하나 적당한 것은 용매의 환류 온도에 가까운 온도로 5~24시간 정도를 행하는 것이 좋다.The whitened callus extract of the present invention can be prepared by a method known in the art, and the method is not particularly limited. Specific examples of the solvent include water, a lower alcohol (methanol, ethanol), a mixture of water and a lower alcohol, acetone, 1,3-butylene glycol, n-propanol , Isopropanol, n-butanol, and mixed solvents thereof are added in a volume of 5 to 20 times by volume, and the mixture is extracted by filtration. The filtrate is concentrated under reduced pressure. Water is added to the concentrate and dispersed, and then an equal amount of a low-polarity organic solvent such as ethyl acetate, chloroform, or diethyl ether is added to the dispersion and shaken. The organic layer is separated and concentrated under reduced pressure to obtain an excellent extract. As the extraction method, 12 to 96 hours in the case of cold beating and percolation, or anhydrous or lower alcohol having 1 to 4 carbon atoms, ethyl acetate or diethyl ether as a solvent, the mixture is allowed to stand at 4 to 25 ° C for 3 to 20 days The active ingredient may be extracted by aging. In the case of warming, it is preferable that the heating is carried out at a temperature close to the reflux temperature of the solvent for 5 to 24 hours, depending on the kind of the solvent to be used and the temperature.
상기와 같이 제조된 백화사설초 추출물은 5-알파 리덕타아제를 저해함으로써 탈모 개선에 강력한 효과를 나타내며, 인체에 무해하고 안전하여 피부 외용제로 제공될 수 있다.The thus-prepared white-fly reed extract has a strong effect on alleviating hair loss by inhibiting 5-alpha reductase, and can be provided as an external preparation for skin, harmless and safe to human body.
본 발명의 피부 외용제 조성물은 백화사설초 추출물을 조성물 총 중량에 대하여 0.0001~50중량%, 보다 바람직하게는 0.01~20중량%의 양으로 함유한다. 이는 0.0001중량% 미만이면 그 효능이 미미하고, 50중량%를 초과하면 함량 증가에 비해 그 효과의 증가가 크지 않기 때문이다.The composition for external application for skin of the present invention contains 0. 5% to 50% by weight, more preferably 0.01% to 20% by weight, based on the total weight of the composition. If the content is less than 0.0001% by weight, the effect is insignificant. If the content is more than 50% by weight, the effect is not increased more than the content is increased.
본 발명에 따른 피부 외용제 조성물은 화장품학 또는 피부과학적으로 허용 가능한 매질 또는 기제를 함유하여 제형화될 수 있다. 이는 국소적용에 적합한 모든 제형으로서, 예를 들면, 용액, 겔, 고체, 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는, 이온형(리포좀) 및 비이온형의 소낭 분산제의 형태로, 또는 크림, 스킨, 로션, 파우더, 연고, 스프레이, 팩, 콘실 스틱, 헤어토닉, 모발 영양화장수, 헤어트리트먼트, 헤어린스, 헤어샴푸, 헤어로션 등의 형태로 제공될 수 있다. 포말(foam)의 형태로 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 사용될 수 있다. 이들 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다. The composition for external application for skin according to the present invention may be formulated containing a cosmetically or dermatologically acceptable medium or base. It may be any formulation suitable for topical application, for example, as a solution, a gel, a solid, a paste anhydrous product, an emulsion obtained by dispersing an oil phase in water, a suspension, a microemulsion, a microcapsule, Such as cream, skin, lotion, powder, ointment, spray, pack, cone stick, hair tonic, hair nutritional lotion, hair treatment, hair conditioner, hair shampoo, hair lotion Lt; / RTI > May also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions may be prepared according to conventional methods in the art.
또한, 본 발명에 의한 피부 외용제 조성물은 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 상기 보조제는 화장품학 또는 피부과학 분야에서 일반적으로 사용되는 양으로 도입된다.In addition, the composition for external application for skin according to the present invention may further comprise at least one selected from the group consisting of a fatty substance, an organic solvent, a solubilizing agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, Or any other conventionally used in cosmetics such as nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics ≪ RTI ID = 0.0 > cosmetics < / RTI > such as botanical ingredients, or adjuvants conventionally used in the field of dermatology. Such adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields.
이하, 시험예 및 실시예를 들어 본 발명의 구성 및 효과를 보다 구체적으로 설명한다. 그러나 이들 시험예 및 실시예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 이에 제한되는 것은 아니다.Hereinafter, the constitution and effects of the present invention will be described in more detail with reference to test examples and examples. However, these test examples and examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited thereto.
[제조예 1] 백화사설초 추출물의 제조[Preparation Example 1] Preparation of Baekhwasa reed extract
백화사설초를 정제수로 세척하고 건조시킨 다음 분쇄한 백화사설초 가루 100g을 에탄올 1L에 넣고 냉각 콘덴서가 달린 추출기에서 12시간 끓여서 추출한 후 300메쉬 여과포로 여과하고, 상기 여과액을 4~15℃에서 7일간 방치하여 숙성시킨 후 와트만 2번 여과지로 여과하여 불용성 물질을 제거하였다. 수득된 여과액을 냉각 콘덴서가 달린 증류 장치를 이용하여 60℃로 감압 농축하였다. 이를 물50㎖에 분산한 후 에틸 아세테이트 300㎖로 다시 추출한 후 유기층을 농축하고 동결 건조하여 건조중량 19.4g의 백화사설초 추출물을 얻었다.100g of crushed white shrimp powder was added to 1L of ethanol, boiled for 12 hours in an extractor equipped with a cooling condenser, filtered through a 300 mesh filter cloth, and the filtrate was filtered at 4 to 15 ° C for 7 days After being left to stand for aging, insoluble matter was removed by filtration through Wattman No. 2 filter paper. The obtained filtrate was concentrated under reduced pressure at 60 占 폚 using a distillation apparatus equipped with a cooling condenser. The mixture was dispersed in 50 ml of water and further extracted with 300 ml of ethyl acetate. The organic layer was concentrated and lyophilized to obtain 19.4 g of white freunds extract of dry weight.
[시험예 1] 5-알파 리덕타아제 저해 효능 평가[Test Example 1] Evaluation of 5-alpha reductase inhibitory efficacy
생후 7∼8주의 성숙한 수컷 스프라그-다우리 랫트(Sprague-Dawley Rat)를 디에틸에테르(diethylether)로 치사시킨 후 복부 전립선을 떼내어 결합조직을 제거하였다. 여기에 완충액[0.32M 수크로스(sucrose), 0.1mM 디티오트레이톨(dithiothreitol), 20mM 아세트산나트륨염(sodium acetate)]을 첨가하고 분쇄기로 잘게 자른 후 현탁하였다. 상기 현탁액을 거즈로 여과한 여과액을 1500X g에서 원심분리한 후 펠렛(pellet)을 취해 상기 완충액을 혼합하여 20~30㎎/㎖ 농도로 현탁하였다.The adult male Sprague-Dawley Rat (7-8 weeks old) was killed with diethylether, and the abdominal prostate was removed to remove connective tissue. To this solution, a buffer solution (0.32 M sucrose, 0.1 mM dithiothreitol, 20 mM sodium acetate) was added, and the mixture was finely pulverized and suspended in a pulverizer. The suspension filtered through gauze was centrifuged at 1500 × g, pellet was taken, and the buffer solution was mixed and suspended at a concentration of 20 to 30 mg / ml.
상기 현탁액의 일부를 취하여 0.02M 인산 완충액에 넣은 후, 동위 원소인 3 H 가 붙어있는 기질 테스토스테론과 함께 반응시켜 생성물인 디하이드로테스토스테론의 생성량을 측정하였다. 이때, 반응 용액은 1mM의 디티오트레이톨, 20mM의 인산염 완충액(pH 6.5), 50μM의 NADPH, [1,2,6,7-3H] 테스토스테론 0.1μCi/테스토스테론(1x10-7M)과 36㎍ 효소 현탁액을 첨가하여 전체 반응액을 565㎕가 되도록 조제하였다.A portion of the suspension was taken in 0.02 M phosphate buffer and reacted with substrate testosterone, which is an isotope, 3 H, to determine the amount of product dihydrootestosterone produced. The reaction solution contained 1 mM dithiothreitol, 20 mM phosphate buffer (pH 6.5), 50 μM NADPH, [1,2,6,7-3H] testosterone 0.1 μCi / testosterone (1 × 10 -7 M) An enzyme suspension was added to prepare a total reaction solution of 565 占 퐇.
상기에서 제조한 백화사설초 추출물 일정량을 10% 디메틸설폭사이드(DMSO)에 녹여 한 반응당 10㎕로 가하고, 대조군으로는 같은 부피의 용매를, 양성 대조군으로는 백자인 추출물을 이용하였다. 백자인 추출물은 상기 제조예 1에서 백화사설초 대신 백자인을 사용한 것을 제외하고는 동일한 방법에 따라 제조하였다.An aliquot of the above-prepared white freunds extract was dissolved in 10% dimethylsulfoxide (DMSO) and added to 10 μl of the reaction. The same volume of the solvent was used as the control, and the white porcelain extract was used as the positive control. The white porcelain extract was prepared in the same manner as in Preparation Example 1, except that white porcelain was used instead of white freckle.
또한, 반응은 상기 준비한 효소 현탁액을 가하여 37℃에서 30분간 진행시킨 후, 600㎕의 에틸아세테이트를 가하여 반응을 정지시키고 생성물을 질소 가스를 통해 건조시켰다. 이를 50㎕의 에틸아세테이트로 녹인 후 전량을 실리카 플라스틱 시트 카이젤겔 60 F 254 (Silica plastic sheet kieselgel 60 F 254 )상에 점적한 후 전개 용매인 에틸아세테이트:사이클로헥산(cyclohexane)(1:1)을 사용하여 전개하였다. 실리카 플라스틱 시트를 자연상태에서 건조시킨 후, 동위원소의 양을 측정하기 위해 바스(Bas, 후지필름, 일본) 시스템을 사용하였으며, 건조된 플라스틱 시트와 노출 필름을 함께 바스 카셋트에 넣어 1주일 동안 보관한 후에 필름에 노출된 테스토스테론과 생성된 디하이드로테스토스테론의 동위원소 양을 노출된 강도를 이용해 정량하였다. IC50값은 2번에 걸쳐 반복 수행하여 평균내었다. 그 결과는 하기 표 1에 나타내었다.The reaction was carried out at 37 ° C for 30 minutes by adding the prepared enzyme suspension, and then 600 μl of ethyl acetate was added to stop the reaction, and the product was dried through nitrogen gas. After dissolving in 50 μl of ethyl acetate, the whole amount was dropped on a silica plastic sheet kiesel gel 60 F 254 (Silica plastic sheet kieselgel 60 F 254), and the developing solvent, ethyl acetate: cyclohexane (1: 1) Respectively. After the silica plastic sheet was dried in a natural state, a system of Bas (Fujifilm, Japan) was used to measure the amount of isotopes. The dried plastic sheet and the exposure film were put in a cassette for 1 week The amount of testosterone exposed to the film and the amount of isotopes of dihydrotestosterone produced were quantitated using the exposed intensity. The IC 50 values were repeated two times and averaged. The results are shown in Table 1 below.
상기 표 1에서 알 수 있듯이, 본 발명에 따른 백화사설초 추출물은 양성 대조군인 백자인 추출물과 유사한 정도로 높은 5-알파 리덕타아제 저해 효과를 나타내었다. 따라서, 본 발명의 백화사설초 추출물은 우수한 5-알파 리덕타아제 저해 효과를 나타내는 것을 확인할 수 있었다.As can be seen from the above Table 1, the Bacillus subtilis extract according to the present invention showed a high inhibitory effect on 5-alpha reductase as similar to the positive control group of white porcelain extract. Thus, it was confirmed that the white freckle extract of the present invention exhibits excellent 5-alpha reductase inhibitory effect.
[실시예 1~2 및 비교예 1][Examples 1 to 2 and Comparative Example 1]
하기 표 2에 기재된 조성에 따라 실시예 1~2 및 비교예 1을 제조하였다. 하기 조성물들은 O/W제형이며, 단위는 중량%이다.Examples 1 to 2 and Comparative Example 1 were produced according to the compositions shown in Table 2 below. The following compositions are O / W formulations and the units are wt.%.
성분Paid
ingredient
성분Awards
ingredient
<실시예 1~2 및 비교예 1의 제조방법>≪ Preparation methods of Examples 1 and 2 and Comparative Example 1 >
(1) 상기 유상성분들을 가열(70~75℃)하여 균일하게 혼합하였다.(1) The oil components were heated (70 to 75 ° C) and mixed uniformly.
(2) 상기 수상성분들을 가열(70~75℃)하여 균일하게 용해 및 혼합하였다.(2) The aqueous phase components were heated (70 to 75 캜) to uniformly dissolve and mix.
(3) 교반하에 온도를 70~75℃로 유지한 상태에서 상기 (2)에 상기 (1)을 투입하여 에멀젼을 만들고 28~30℃까지 냉각하였다.(3) The emulsion was prepared by adding the above-mentioned (1) to the above (2) while maintaining the temperature at 70 to 75 캜 under stirring, and the emulsion was cooled to 28 to 30 캜.
[시험예 2] 여드름 개선 효능 평가[Test Example 2] Evaluation of acne improvement efficacy
여드름을 보유하고 있는 12명에게 상기 실시예 1~2 및 비교예 1을 한 달간 사용하게 하였다.Twelve individuals with acne were allowed to use Examples 1 and 2 and Comparative Example 1 for one month.
여드름 개선 척도는 1점에서 5점까지로 하고, 1점은 '아니다', 3점은 '보통이다', 5점은 '매우 그렇다'로 표기하도록 하였다. 실험 결과는 하기의 표 3에 12명의 평균점수로 표기하였다. Acne improvement scale is from 1 point to 5 points, 1 point is 'No', 3 points are 'Normal' and 5 points are 'Very agree'. The experimental results are shown in the following Table 3 as the average score of 12 persons.
여드름 소멸 시기는 소멸이 판독된 일수를 기준으로 하였으며, 여드름 재발은 유무로 1개월 뒤의 결과를 기준으로 하였다. The acne extermination period was based on the number of days of disappearance readings, and the results were based on the results after 1 month with or without recurrence of acne.
피지분비감소는 1점에서 5점까지로 하고, 1점은 '아니다', 3점은 '보통이다', 5점은 '매우 그렇다'로 표기하도록 하였다. 실험 결과는 하기 표 3에 12명의 평균점수로 표기하였다. The reduction of sebaceous secretion was from 1 point to 5 points, 1 point was 'No', 3 points were 'Normal' and 5 points were 'Very agree'. Experimental results are shown in Table 3 below with an average score of 12 persons.
피부자극의 유무는 (자극반응을 보인 명수)/(총 시험자수)로 보았다.The presence or absence of skin irritation was evaluated as (number of stimuli) / (total number of test subjects).
상기 표 3에서 알 수 있듯이, 본 발명에 따른 백화사설초 추출물을 함유하는 피부 외용제 조성물(실시예 1~2)은 여드름이 재발되지 않았고, 염증성 여드름 개선에 대해 평균 4.2점 이상, 면포성 여드름 소멸시기에 대해 평균 3.4일 이하, 피지분비 감소에 대해 평균 4.5점 이상을 획득하여 피부 자극 없이 여드름 개선에 우수한 효과를 나타내었다. 반면, 본 발명의 백화사설초 추출물을 함유하지 않는 피부 외용제 조성물(비교예 1)은 여드름 개선 및 피지 분비 감소 효과가 없었다.As can be seen from Table 3, the composition for external application for skin containing the extract of Bacillus subtilis according to the present invention (Examples 1 and 2) showed no recurrence of acne, a mean score of 4.2 or higher for improvement of inflammatory acne, To 3.4 days and an average of 4.5 points for the reduction of sebum secretion, and showed excellent effect on acne improvement without skin irritation. On the other hand, the composition for external application for skin, which does not contain the extract of Paeonia spp. Of the present invention (Comparative Example 1), did not have the effect of improving acne and reducing sebum secretion.
[시험예 3] 탈모 개선 효과 시험[Test Example 3] Test for improving hair loss
탈모량이 비교적 많은 25 내지 40세의 남성 20명을 선정하여 하기 표 4에 기재된 샴푸 조성물을 1일 1회씩 1개월 동안 사용하게 한 후, 관능 검사를 실시하여 탈모 개선 효과를 하기 평가기준에 따라 평가하고, 그 결과를 표 5에 나타내었다.20 male subjects aged 25 to 40 years with relatively high hair loss amount were selected and the shampoo composition described in Table 4 was used once a day for one month. Then, sensory evaluation was performed to evaluate the effect of improving hair loss according to the following evaluation criteria And the results are shown in Table 5.
(중량%)Example 3
(weight%)
(중량%)Example 4
(weight%)
(중량%)Comparative Example 2
(weight%)
<평가기준><Evaluation Criteria>
1: 오히려 개선되지 않았다.1: It was not improved.
2: 그저 그렇다.2: Just so.
3: 조금 개선되었다.3: A little improved.
4: 어느 정도 개선되었다.4: Some improvement.
5: 상당한 개선 효과를 보였다.5: Significant improvement.
상기 표 5로부터 알 수 있듯이, 본 발명의 백화사설초 추출물을 함유하는 실시예 3~4는 유효성분을 함유하지 않는 비교예 2보다 우수한 탈모 개선 효과를 나타내었다. As can be seen from the above Table 5, Examples 3 to 4 containing the white freund's extract of the present invention showed better hair loss improving effect than Comparative Example 2 containing no active ingredient.
[제형예 1] 영양화장수[Formulation Example 1] Nutritional lotion
하기 표 6에 기재된 조성에 따라 통상적인 방법으로 영양화장수를 제조하였다.Nutrition lotion was prepared according to a conventional method according to the composition shown in Table 6 below.
[제형예 2] 영양로션[Formulation Example 2] Nutrition lotion
하기 표 7에 기재된 조성에 따라 통상적인 방법으로 영양로션을 제조하였다.Nutrition lotions were prepared in a conventional manner according to the composition shown in Table 7 below.
[제형예 3] 영양크림[Formulation Example 3] Nourishing cream
하기 표 8에 기재된 조성에 따라 통상적인 방법으로 영양크림을 제조하였다.Nutritive creams were prepared according to the compositions listed in Table 8 below in a conventional manner.
[제형예 4] 팩[Formulation Example 4] Pack
하기 표 9에 기재된 조성에 따라 통상적인 방법으로 팩을 제조하였다.Packs were prepared in a conventional manner according to the composition shown in Table 9 below.
[제형예 5] 연고[Formulation Example 5] Ointment
하기 표 10에 기재된 조성에 따라 통상적인 방법으로 연고를 제조하였다.Ointments were prepared in a conventional manner according to the composition shown in Table 10 below.
[제형예 6] 헤어토닉[Formulation Example 6] Hair tonic
하기 표 11에 기재된 조성에 따라 통상적인 방법으로 헤어토닉을 제조하였다.A hair tonic was prepared according to the composition shown in Table 11 by a conventional method.
[제형예 7] 헤어로션[Formulation Example 7] Hair lotion
하기 표 12에 기재된 조성에 따라 통상적인 방법으로 헤어로션을 제조하였다.Hair lotions were prepared in a conventional manner according to the composition shown in Table 12 below.
[제형예 8] 헤어린스 및 트리트먼트[Formulation Example 8] Hair rinse and treatment
하기 표 13에 기재된 조성에 따라 통상적인 방법으로 헤어린스 및 트리트먼트를 제조하였다.Hair rinses and treatments were prepared in a conventional manner according to the composition shown in Table 13 below.
Claims (6)
상기 백화사설초 추출물은 백화사설초를 에탄올로 추출하여 얻은 여과액을 4~15℃에서 숙성시킨 다음, 에틸아세테이트로 재추출한 것이고,
상기 백화사설초 추출물은 조성물 총 중량에 대하여 0.01~20중량%의 양으로 함유되는 것을 특징으로 하는, 화장료 조성물.
A cosmetic composition for improvement of underwater type (O / W) hair loss comprising an extract of Baekhwa exclusive use as an active ingredient,
The Baekhwasa reed extract is obtained by extracting Baekhwasaeol with ethanol and aging at 4 ~ 15 ℃ and then re-extracting with ethyl acetate.
The cosmetic composition according to claim 1, wherein the whitening agent extract is present in an amount of 0.01 to 20% by weight based on the total weight of the composition.
The cosmetic composition according to claim 1, wherein the white freckle extract inhibits 5-alpha reductase.
The cosmetic composition according to claim 1, wherein the white freckle extract is contained in an amount of 1% by weight or 10% by weight based on the total weight of the composition.
The composition of claim 1, wherein the composition is selected from the group consisting of fats, organic solvents, solubilizers, thickeners, gellants, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, At least one selected from the group consisting of nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, wetting agents, oils, dyes, pigments, hydrophilic active agents, lipophilic active agents and lipid vesicles ≪ / RTI >
The composition of claim 1, wherein the composition is in the form of a gel, an emulsion, a suspension, a microemulsion, a microcapsule, a fine granule, a cream, a skin, a lotion, a powder, an ointment, a spray, a pack, a cone stick, Wherein the cosmetic composition is formulated into any one selected from the group consisting of hair, hair, hair shampoo, hair lotion, and aerosol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170062536A KR101825603B1 (en) | 2017-05-19 | 2017-05-19 | Composition of skin external application for improving alopecia containing Oldenlandia Diffusa Willd extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170062536A KR101825603B1 (en) | 2017-05-19 | 2017-05-19 | Composition of skin external application for improving alopecia containing Oldenlandia Diffusa Willd extracts |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100071030A Division KR20120009915A (en) | 2010-07-22 | 2010-07-22 | Skin external preparation composition for acne and hair loss improvement |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170059939A KR20170059939A (en) | 2017-05-31 |
KR101825603B1 true KR101825603B1 (en) | 2018-02-05 |
Family
ID=59052702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170062536A Active KR101825603B1 (en) | 2017-05-19 | 2017-05-19 | Composition of skin external application for improving alopecia containing Oldenlandia Diffusa Willd extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101825603B1 (en) |
-
2017
- 2017-05-19 KR KR1020170062536A patent/KR101825603B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20170059939A (en) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101017709B1 (en) | Cosmetic composition having the effect of preventing hair loss, inhibiting dandruff, and promoting hair growth containing complex herbal extracts such as ginseng | |
KR102142311B1 (en) | Skin external composition comprising tangeretin | |
JP2000143479A (en) | Whitening cosmetics | |
US6465023B2 (en) | Cosmetic, dermatological and pharmaceutical use of an extract of Terminalia catappa | |
JP2003160461A (en) | Skin care preparation | |
BR102014003213B1 (en) | Use of blackberry extract to improve hair or hair growth | |
KR101322850B1 (en) | The cosmetic composition for pore-minimizing and inhibition of Sebum Secretion containing the extract of leaves of Mentha arvensis var. piperascens, wheat bud, and Platycodon grandiflorum | |
KR101825603B1 (en) | Composition of skin external application for improving alopecia containing Oldenlandia Diffusa Willd extracts | |
JP5000964B2 (en) | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression | |
JPH08133950A (en) | Skin preparation for external use | |
JPH08133948A (en) | Skin preparation for external use | |
KR20120009915A (en) | Skin external preparation composition for acne and hair loss improvement | |
JPH1179948A (en) | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion | |
JPH0873340A (en) | Skin external preparation | |
KR101791488B1 (en) | Composition of skin external application for alleviating stimulation caused from ultraviolet ray containing Oldenlandia Diffusa Willd extracts | |
KR102093708B1 (en) | A cosmetic composition using Fraxini cortex extract | |
KR100444102B1 (en) | Cosmetic composition for trichogenousness containing Thujae semen extract | |
KR102365222B1 (en) | Low irritating cosmetic composition for skin whitening comprising albutin, Polygonum tinctorium leaf and Betula platyphylla japonica bark extract | |
KR102365223B1 (en) | Low irritating cosmetic composition for skin whitening comprising albutin, Polygonum tinctorium leaf and Brassica napus whole plant | |
JP4473439B2 (en) | Whitening agent | |
JPH11124313A (en) | External preparation for skin whitening | |
KR101924355B1 (en) | Composition for anti-stretch mark effect on the skin containing extracts of salicornia herbacea and ecklonia cava | |
JP2001302528A (en) | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR, AGENT FOR HAIR AND SKIN COSMETIC | |
JP2006241033A (en) | Skin care preparation for external use for amelioration of skin somberness | |
JP6433678B2 (en) | External preparations and internal preparations containing the extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20170519 Patent event code: PA01071R01D Filing date: 20100722 Application number text: 1020100071030 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170621 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20171219 |
|
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180130 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20180131 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20201228 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20211221 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20241223 Start annual number: 8 End annual number: 8 |